Market Cap
$121.9M
VTVT
vTv Therapeutics Inc.
$31.36 ▼ -1.54%
Prev close $31.85Market cap$121.9M
ConsensusStrong Buy
12-mo target$54.71 (+74.5%)
▲ Bullish
Analyst conviction 9/10
3 New Institutional Positions3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VTVT right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
27 funds
Inst. Value
$37.0M
Inst. Activity
3 buys / 3 sells
SEC Reports
2
Press Releases
2
Price chart 30d -6.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 15, 2026 other
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — NEAR_EXIT
3 shares (—)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
269,874 shares ($10.2M)
Jun 26, 2026 Insider
AKKARAJU SRINIVAS was granted 6,000 shares
Director @ $35.08 ($210.5K)
Jun 26, 2026 Insider
Al-Marzooqi Fahed was granted 6,000 shares
Director @ $35.08 ($210.5K)
Jun 26, 2026 Insider
Jun 10, 2026 SEC Phillips Anne M. was granted 6,000 shares
Director @ $35.08 ($210.5K)
vTv Therapeutics filed a DEFA14A to correct an inadvertent omission from its 2026 proxy statement, adding an advisory vo
DEFA14A — Impact 3/10
vTv Therapeutics granted 39,500 stock options to two non-executive employees as inducement awards. This is a routine com
Impact 2/10
Analyst ratings buy % +2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 16, 2026 | BTIG | MAINTAIN | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Aug 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% |
Price targets
Where 7 covering analysts think VTVT trades over the next 12 months.
$54.71 +74.5% upside Strong Buy
Current$31.36 Low$42.00 Median$57.00 High$67.00 7 analysts
$42.00$67.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 3.5/10.Plus 2 press releases.
NEUTRALDEFA14A3/10
vTv Therapeutics filed a DEFA14A to correct an inadvertent omission from its 2026 proxy statement, a
Jun 10, 2026
NEUTRAL8-K4/10
vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is
Feb 26, 2026
NEUTRAL2/10
vTv Therapeutics granted 39,500 stock options to two non-executive employees as inducement awards. T
May 8, 2026
MIXED6/10
vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash
Mar 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 15, 2026
other
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the devel
Sep 2, 2026
other
vTv Therapeutics to Participate in September Investor Conferences
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadiseglia
Aug 10, 2026
earnings_calendar
VTVT Q2 2026 Earnings Scheduled — 2026-08-10
Aug 6, 2026
earnings
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026
Jul 2, 2026
regulatory
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the develo
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.18 | $-1.29–$-1.06 | -9.0% | -1.5% | 1↑ 1↓ | $0.0B | 4 |
| Next Q | $-1.17 | $-1.32–$-1.06 | -101.7% | -1.4% | 2↑ 0↓ | $0.0B | 4 |
| Current FY | $-2.22 | $-4.20–$-1.31 | 30.7% | +8.0% | 1↑ 0↓ | $0.0B | 4 |
| Next FY | $-4.70 | $-7.81–$-2.61 | -112.0% | -11.8% | 1↑ 1↓ | $0.0B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.177 | — |
| 7d ago | $-1.177 | — |
| 30d ago | $-1.160 | -0.018 |
| 60d ago | $-1.042 | -0.135 |
| 90d ago | $-1.042 | -0.135 |
Institutional ownership
Which big funds own VTVT (from quarterly 13F filings) and who is adding or trimming.
27 institutional holders with $37.0M total value (989,058 shares) as of 2026-Q2. Top holders: ROYAL, MILLENNIUM, FMR.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 3 | $0.00 | 0.0% | NEAR_EXIT -93.0% |
| MILLENNIUM MANAGEMENT LLC | 269,874 | $10.2M | 27.4% | ADD +30.8% |
| FMR LLC | 260,391 | $9.8M | 26.5% | ADD +39.4% |
| BAKER BROS. ADVISORS LP | 148,314 | $5.6M | 15.1% | ADD +52.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 94,463 | $3.6M | 9.6% | — |
| MARSHALL WACE, LLP | 39,560 | $1.5M | 4.0% | DOUBLED +195.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 32,470 | $1.2M | 3.3% | ADD +84.3% |
| RENAISSANCE TECHNOLOGIES LLC | 17,454 | $657.1K | 1.8% | — |
| VANGUARD FIDUCIARY TRUST CO | 16,239 | $611.4K | 1.7% | — |
| BlackRock, Inc. | 14,731 | $554.6K | 1.5% | DOUBLED +114.9% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | NEAR_EXIT | 43 | 3 | -93.0% | — |
| MILLENNIUM MANAGEMENT LLC | ADD | 206,288 | 269,874 | +30.8% | $10.2M |
| MARSHALL WACE, LLP | DOUBLED | 13,389 | 39,560 | +195.5% | $1.5M |
| NORTHERN TRUST CORP | TRIM | 18,052 | 6,123 | -66.1% | $230.5K |
| UBS Group AG | TRIM | 5,636 | 2,175 | -61.4% | $81.9K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 9 | 1,802 | +19922.2% | $67.8K |
| UBS Group AG | DOUBLED | 1,668 | 5,636 | +237.9% | $223.5K |
| FMR LLC | ADD | 192,891 | 268,856 | +39.4% | $10.8M |
| VANGUARD GROUP INC | ADD | 46,990 | 83,400 | +77.5% | $3.3M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 15,298 | 28,194 | +84.3% | $1.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 5 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | AKKARAJU SRINIVAS | Director | AWARD | 6,000 | $35.08 | $210.5K |
| Jun 26, 2026 | Al-Marzooqi Fahed | Director | AWARD | 6,000 | $35.08 | $210.5K |
| Jun 26, 2026 | Phillips Anne M. | Director | AWARD | 6,000 | $35.08 | $210.5K |
| Jun 26, 2026 | SPIEGELMAN DANIEL K | Director | AWARD | 6,000 | $35.08 | $210.5K |
| Jun 26, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 6,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VTVT.
Shares short
160,312
Settlement Sep 15, 2026
Change vs prior
-1.6%
Semi-monthly cycle
Days to cover
5.0
At avg daily volume
Of shares outstanding
≈4.0%
Estimate — not % of float
All VTVT filing & press-release reports (4)
- DEFA14A reportJun 10, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMar 10, 2026
- 8-K reportFeb 26, 2026